26 – 27 October, 2026 | Embassy of France, Washington, D. C., USA

A Multi-stakeholder Multi-specialty
NASH Trialists Think Tank

Metabolic, hepatology, nephrology & cardiovascular cross-talk

19 - 20 October, 2023

Georgetown University, Leavey Center, Washington, D. C.
ACCESS LIVE STREAM
DOWNLOAD AGENDA
DOWNLOAD AGENDA

Download Virtual Connection Guide

Organized by
In collaboration CVCT Logo
Endorsed by the Stravitz-Sanyal Institute for
Liver Disease and Metabolic Health
Download Agenda
About Why should you attend? Faculty Program Sponsors Topics
Organized by
assets-05
In collaboration with
cvc
Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Download Agenda
Download Agenda
Organized by
In collaboration CVCT Logo
Endorsed by the Stravitz-Sanyal Institute for
Liver Disease and Metabolic Health

19 – 20 October,
2023

Embassy of France
4101 Reservoir Road, NW – Washington, D.C. – 20007

Download Agenda
Organized by
In collaboration

Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health

assets-04
Download Agenda
Organized by
assets-05
In collaboration with
cvc
assets-07
Endorsed by the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Overview
Overview Topics Speakers Learning Objectives Program Sponsors
What This Moment Means - And Why MOSAIC Matters
Now in its fifth edition, MOSAIC is the only global, mission-driven forum where the boundaries between hepatology, cardiology, nephrology, and endocrinology dissolve - replaced by a shared commitment to advancing MASLD/MASH science across organ systems. What distinguishes MOSAIC is not its size, but its composition: trialists, regulators, patients, journal editors, payers, and industry leaders - every voice in the room shapes the outcome. .
Special Announcement
It is with deep sadness that the MOSAIC team learned of the passing of Prof Stephen Harrison on 4/24/2024. Prof. Harrison was one of the key members in the MOSAIC project and will be greatly missed for his commitment to a multi organ and multi disciplinary approach to MASH/ MAFLD.
A Defining Moment For MASH And Multi-Organ Medicine
For decades, MASH was considered one of biopharmaʼs most intractable challenges. That era is over. The approval of the first MASH therapies, the expansion of established metabolic drugs into liver disease, and a wave of strategic acquisitions have transformed the landscape.

But the real paradigm shift runs deeper. A new cross-organ thinking is emerging - formalized in the Cardiovascular–Kidney–Liver–Metabolic (CKLM) framework championed by the MOSAIC consortium and now published as a peer-reviewed roadmap. MASLD and MASH are no longer understood as isolated liver conditions: they sit at the center of an interconnected syndrome where cardiovascular events remain the leading cause of death and where kidney, metabolic, and hepatic pathways converge. This demands a fundamentally different approach to clinical trial design.
MOSAIC - the 1st Global NASH Trialist Forum
will bring together cardiology, endocrinology & hepatology clinical trialists, industry, regulatory experts, payers, patients representatives and other stakeholders to further advance collective intelligence and foster collaboration about NASH diagnosis and management.
Who can participate?
Overview Topics Speakers Learning Objectives Program Sponsors
Mosaic is an invitation only event for clinical trialists, investigators, methodologists, regulators, clinical research organizations, clinicians, epidemiologists, statisticians, payers, industry R&D experts, major journal editors, patients, patient trialists and patient advocacy representatives.
Why should you attend?

Now in its fifth edition, MOSAIC is the only global, mission-driven forum where the boundaries between hepatology, cardiology, nephrology, and endocrinology dissolve – replaced by a shared commitment to advancing MASLD/MASH science across organ systems. What distinguishes MOSAIC is not its size, but its composition: trialists, regulators, patients, journal editors, payers, and industry leaders – every voice in the room shapes the outcome. 

Regulatory milestones are accelerating

  • The first MASH therapies have been approved, and the first-ever non-invasive biomarker has been accepted into formal regulatory qualification. MOSAIC offers a unique opportunity to engage in in-depth, multistakeholder discussions with regulators on surrogate endpoint qualification and approval pathways

The CKLM framework is being operationalized

  • The MOSAIC consortium is drafting template protocols for integrated multi-organ trials that keep MASLD/MASH at their center while capturing cardiovascular, kidney, and metabolic endpoints. This work is setting new standards for how liver disease is studied in a systemic context.

Combination therapy demands new trial architectures

  • Master protocols, basket trials, platform designs, and novel endpoint frameworks are being shaped in real time at MOSAIC - in a setting that values scientific rigor and multidisciplinary exchange.

Noninvasive diagnostics are approaching regulatory acceptance

  • MOSAIC addresses the tools that will replace liver biopsy in MASH trial design - and the validation pathways required to get there.

Cross-specialty alignment is no longer optional

  • Hepatologists, cardiologists, nephrologists, endocrinologists, regulators, patients, and journal editors must converge on endpoints and substudies - or risk perpetuating the data gaps that have slowed the field. MOSAIC is the one place where this convergence happens.
Faculty
Javed Butler (USA)
Javed Butler
USA
Veronica Miller
USA
Arun Sanyal
USA
chair-eclipse
Faiez Zannad
France
See all faculty
Topics
  • MASH – Cardiovascular intersections
  • Epidemiology, disease mechanisms
  • Non-invasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in MASH trials
View full agenda
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
View full agenda
Topics
  • NASH – Cardiovascular Intersection
  • Epidemiology, disease mechanisms
  • NonInvasive Tests (NITs)
  • Trial design issues and innovations
  • Patient population selection in NASH trials
  • Endpoints
  • Pathways to approval
  • Therapeutics
  • Experiences and case studies
View full agenda
Become a sponsor